Graid Technology Inc.
With SupremeRAID™ v1.6, Double Failure Protection Guarantees Seamless Access to Vital Data, Empowering Customers With Reliability and Peace of Mind
SANTA CLARA, CA / ACCESSWIRE / April 23, 2024 / Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its new software release, SupremeRAID™ v1.6. This new feature set addresses critical data integrity issues associated with double failures in RAID configurations.
New double failure protection provides maximum RAID stability with minimal impact on overall system performance.
A double failure occurs when a RAID system experiences a power outage or an unclean shutdown during the rebuilding of data from a previous disk failure. Traditionally, RAID systems utilize a persistent journal to log every I/O transaction and its corresponding parity. This method ensures that in-progress I/O operations and their parities can be recovered. The use of a single device to store this persistent journal has become a significant single point of failure and a bottleneck in modern NVMe SSD RAID configurations. Until now, this challenge has remained unaddressed in the market. With SupremeRAID™ v1.6, the distributed journal feature is designed to eliminate this single point of failure and significantly improve performance bottlenecks by distributing data and parity across all disks in a RAID group and redundantly journaling to provide maximum RAID stability with minimal impact on overall system performance.
"With data and parity already distributed across every disk in a RAID group," said Leander Yu, CEO of Graid Technology, "our new distributed journal feature is the perfect design to ensure maximum data integrity while maintaining high performance levels."
Graid Technology is excited to announce that it will commence the distribution of the SupremeRAID™ v1.6 beta version to its OEM customers and key global accounts in early May. The public release of SupremeRAID™ v1.6 is scheduled for late June. This new version will simultaneously be available for all Graid Technology products.
Graid Technology is headquartered in Silicon Valley, California, with an R&D center in Taipei, Taiwan. Winners of the esteemed Tech Trailblazers Storage Award for 2023 and the 2023 Golden Award at the Asia Pacific ICT Alliance, SupremeRAID™ performance is breaking world records as the first NVMe and NVMeoF RAID card to unlock the full potential of your SSD performance: a single SupremeRAID™ card delivers 28 million IOPS and 260GB/s of throughput. For more information on Graid Technology, visit www.graidtech.com or connect with us on Twitter or LinkedIn.
Contact Information
Andrea Eaken
Director of Marketing, Americas & EMEA | Graid Technology
andrea.eaken@graidtech.com
949-742-9928
Related Files
April 2024 SupremeRAID Brochures and Specs
Unleash the Performance of PCIe Gen 5 with Supermicro SupremeRAID KIOXIA_white paper
SOURCE: Graid Technology, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
PHYLA Announces a Series of International Collaborations With the University of Bradford and UPM and a Significant Government-Supported Land Regeneration Project in the Gambia10.12.2024 14:00:00 CET | Press release
LONDON, UK PHYLA and the University of Bradford join forces to develop marketable compounds, cosmetics and superfood products from the pongamia plant PHYLA has entered into a commercial agreement with the University of Bradford to develop marketable bio-compounds for cosmetics and superfood products derived from the pongamia (oil tree) plant which are cultivated in PHYLA's land regeneration projects. The partnership aims to leverage PHYLA's existing IP by applying specific extraction technologies which maximise the yield and value of bio-compounds and other plant-based products. Phyla's Pongamia Pods Phyla's high-density pongamia pod cluster Professor Anant Paradkar, Director of The Centre for Pharmaceutical Engineering Science (CPES) at the University of Bradford, commented: "We are thrilled to collaborate with PHYLA to advance the development of plant-based products. Our Centre has a long-standing commitment to green and sustainable extraction technologies, and this partnership align
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom